Drug intelligence / Profile preview

Vanqua Bio C5aR1 antagonist

Development stage: Preclinical
Lead developer: Biogen
Modality: Small Molecules
Administration: Oral

Overview

Vanqua Bio is developing CNS-penetrant small molecule antagonists of the C5aR1 (complement component 5a receptor 1) for the treatment of Alzheimer's disease and other neurodegenerative diseases. These compounds are designed to cross the blood-brain barrier and target C5aR1 in the central nervous system to reduce neuroinflammation and slow disease progression. This program is distinct from Vanqua's peripheral C5aR1 antagonist, VQ-201, which was licensed to Biogen in October 2025. The program is currently in preclinical development and represents a first-in-class approach to targeting complement-mediated neuroinflammation in the brain.

Other names: C5aR1 antagonist (CNS)

Targets

C5AR1 (Complement C5a receptor 1)

Beyond the preview

Go deeper on Vanqua Bio C5aR1 antagonist.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vanqua Bio C5aR1 antagonist.

Explore the full profile